ECU
NBIX icon

Eisler Capital (UK)’s Neurocrine Biosciences NBIX Stock Holding History

Eisler Capital (UK)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,928
Closed -$4.13M – 599
2024
Q1 		$4.13M Buy
29,928
+23,085
+337% +$3.15M 0.03% 338
2023
Q4 		$902K Buy
+6,843
New +$788K 0.01% 514

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Eisler Capital (UK)'s NBIX Position: Q2 2024 in Review

Eisler Capital (UK) sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 29,928 shares — an estimated $4.13M sold.

Eisler Capital (UK) first reported a position in NBIX in Q4 2023 and held it in 2 quarters. The position peaked at $4.13M in Q1 2024. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Eisler Capital (UK) reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Eisler Capital (UK) sold 29,928 Neurocrine Biosciences shares in Q2 2024, an estimated $4.13M.
  • Eisler Capital (UK) first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 2 quarters.
  • Eisler Capital (UK)'s Neurocrine Biosciences position peaked at $4.13M in Q1 2024.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Eisler Capital (UK)'s 13F filing for Q2 2024, filed 13 Aug 2024.